What is the current valuation of the Germany meningococcal vaccines market?

The market valuation was 252.45 USD Million in 2024. Read More

What is the projected market size for the Germany meningococcal vaccines market by 2035?

The projected valuation for 2035 is 367.95 USD Million. Read More

What is the expected CAGR for the Germany meningococcal vaccines market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 3.48%. Read More

Which companies are the key players in the Germany meningococcal vaccines market?

Key players include Pfizer, Sanofi, GlaxoSmithKline, Merck & Co., Novartis, Bavarian Nordic, AstraZeneca, and Serum Institute of India. Read More

What are the main applications of meningococcal vaccines in Germany?

Main applications include Vaccination Programs, Travel Vaccination, Routine Immunization, Outbreak Response, and Healthcare Settings. Read More

How does the market perform across different age groups for meningococcal vaccines?

The market segments by age group include Infants, Children, Adolescents, Adults, and the Elderly, with Adults projected to generate 80.0 to 120.0 USD Million. Read More

What distribution channels are utilized for meningococcal vaccines in Germany?

Distribution channels include Direct Sales, Wholesale Distribution, Online Sales, and Pharmacy Distribution, with Pharmacy Distribution expected to yield 102.45 to 142.95 USD Million. Read More

What types of meningococcal vaccines are available in the German market?

Available vaccine types include Conjugate Vaccines, Polysaccharide Vaccines, Recombinant Vaccines, and Combination Vaccines. Read More

How do hospitals and clinics contribute to the meningococcal vaccines market in Germany?

Hospitals and Clinics are projected to generate 60.0 to 90.0 USD Million and 50.0 to 75.0 USD Million, respectively. Read More

What is the significance of public health organizations in the meningococcal vaccines market?

Public Health Organizations are expected to contribute 70.0 to 100.0 USD Million to the market. Read More

Germany Meningococcal Vaccines Market

Germany Meningococcal Vaccines Market Research Report: Size, Share, Trend Analysis By Vaccine Type (Monovalent Vaccines, Multivalent Vaccines, Conjugate Vaccines), By Age Group (Infants, Children, Adolescents, Adults), By Administration Route (Intramuscular, Subcutaneous, Oral) and By Distribution Channel (Hospitals, Clinics, Pharmacies) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

3.48%

2024 Market Size

$ 252.45 Million

2035 Market Size

$ 367.95 Million

Pharmaceutical ● Updated February 2026 Report ID: MRFR/Pharma/51386-HCR | Pages: 200 | Author: Vikita Thakur, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Million)
  1. 4.1.1 Vaccination Programs
  2. 4.1.2 Travel Vaccination
  3. 4.1.3 Routine Immunization
  4. 4.1.4 Outbreak Response
  5. 4.1.5 Healthcare Settings
2. 4.2 Healthcare, BY End Use (USD Million)
  1. 4.2.1 Hospitals
  2. 4.2.2 Clinics
  3. 4.2.3 Pharmacies
  4. 4.2.4 Public Health Organizations
  5. 4.2.5 Educational Institutions
3. 4.3 Healthcare, BY Age Group (USD Million)
  1. 4.3.1 Infants
  2. 4.3.2 Children
  3. 4.3.3 Adolescents
  4. 4.3.4 Adults
  5. 4.3.5 Elderly
4. 4.4 Healthcare, BY Vaccine Type (USD Million)
  1. 4.4.1 Conjugate Vaccines
  2. 4.4.2 Polysaccharide Vaccines
  3. 4.4.3 Recombinant Vaccines
  4. 4.4.4 Combination Vaccines
5. 4.5 Healthcare, BY Distribution Channel (USD Million)
  1. 4.5.1 Direct Sales
  2. 4.5.2 Wholesale Distribution
  3. 4.5.3 Online Sales
  4. 4.5.4 Pharmacy Distribution
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (DE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Sanofi (FR)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 GlaxoSmithKline (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck & Co. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bavarian Nordic (DK)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Serum Institute of India (IN)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GERMANY MARKET ANALYSIS BY APPLICATION
3. 6.3 GERMANY MARKET ANALYSIS BY END USE
4. 6.4 GERMANY MARKET ANALYSIS BY AGE GROUP
5. 6.5 GERMANY MARKET ANALYSIS BY VACCINE TYPE
6. 6.6 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
17. 6.17 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Million)
19. 6.19 HEALTHCARE, BY VACCINE TYPE, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY VACCINE TYPE, 2024 TO 2035 (USD Million)
21. 6.21 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.2.2 BY END USE, 2026-2035 (USD Million)
  3. 7.2.3 BY AGE GROUP, 2026-2035 (USD Million)
  4. 7.2.4 BY VACCINE TYPE, 2026-2035 (USD Million)
  5. 7.2.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Germany Meningococcal Vaccines Market Segmentation

Germany Meningococcal Vaccines Market By Application (USD Million, 2026-2035)

Vaccination Programs
Travel Vaccination
Routine Immunization
Outbreak Response
Germany Meningococcal Vaccines Market Settings

Germany Meningococcal Vaccines Market By End Use (USD Million, 2026-2035)

Hospitals
Clinics
Pharmacies
Public Health Organizations
Educational Institutions

Germany Meningococcal Vaccines Market By Age Group (USD Million, 2026-2035)

Infants
Children
Adolescents
Adults
Elderly

Germany Meningococcal Vaccines Market By Vaccine Type (USD Million, 2026-2035)

Conjugate Vaccines
Polysaccharide Vaccines
Recombinant Vaccines
Combination Vaccines

Germany Meningococcal Vaccines Market By Distribution Channel (USD Million, 2026-2035)

Direct Sales
Wholesale Distribution
Online Sales
Pharmacy Distribution

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”